While the clinical benefit of proteasome inhibitors (PIs) for multiple myeloma (MM) treatment remains unchallenged, dose-limiting toxicities and the inevitable emergence of drug resistance limit their long-term utility. Disease eradication is compromised by drug resistance that is either present de novo or therapy-induced, which accounts for the majority of tumor relapses and MM-related deaths. Non-coding RNAs (ncRNAs) are a broad class of RNA molecules, including long non-coding RNAs (lncRNAs), that do not encode proteins but play a major role in regulating the fundamental cellular processes that control cancer initiation, metastasis, and therapeutic resistance. While lncRNAs have recently attracted significant attention as therapeutic targets to potentially improve cancer treatment, identification of lncRNAs that are deregulated in cells resistant to PIs has not been previously addressed. We have modeled drug resistance by generating three MM cell lines with acquired resistance to either bortezomib, carfilzomib, or ixazomib. Genome-wide profiling identified lncRNAs that were significantly deregulated in all three PI-resistant cell lines relative to the drug-sensitive parental cell line. Strikingly, certain lncRNAs deregulated in the three PI-resistant cell lines were also deregulated in MM plasma cells isolated from newly diagnosed patients compared to healthy plasma cells. Taken together, these preliminary studies strongly suggest that lncRNAs represent potential therapeutic targets to prevent or overcome drug resistance. More investigations are ongoing to expand these initial studies in a greater number of MM patients to better define lncRNAs signatures that contribute to PI resistance in MM.
Introduction
Multiple myeloma (MM) is characterized by the clonal proliferation of malignant plasma cells (PCs) within the bone marrow (BM) microenvironment [1, 2] . MM is the second most common hematologic malignancy, with an incidence of 24,000 cases per year in the USA, and accounts for 2% of deaths from all cancers and ≈20% of deaths from hematologic cancers [3] . In Western countries, in the near future both the incidence and prevalence of this disease will increase as the result of an aging population and increased survival of those with the disease. As the number of patients surviving with MM increases, concern for the development of therapeutic resistance rises. Although the introduction
Cell Growth and Proliferation
The effect of proteasome inhibitors on myeloma growth and proliferation was assessed by measuring XTT (Sigma) dye absorbance. First, 5 × 10 4 cells were plated in 96-well plates and incubated in media that lacked phenol red. Cells were then treated with drugs at the indicated concentration (10 nM) and incubated for 72 h. XTT-phenazine methosulfate (PMS) mixture (50 µL, 1 mg/mL XTT; 20 µM PMS) was prepared and added to plates that were then incubated for 4 h. Absorbance was then measured using a BMG Labtech FLUOstar OPTIMA plate reader (Ortenberg, Germany).
Detection of Apoptosis
First, 1 × 10 6 myeloma cells were cultured for 24 h in a medium with or without PIs. Cells were harvested, washed, and stained with annexin V/propidium iodide (PI). Annexin V + /PI − apoptotic cells were enumerated using the Epics flow cytometer (Beckman Coulter, Indianapolis, IN, USA). The percentage of cells undergoing apoptosis was defined as the sum of early apoptosis (annexin V + ) and late apoptosis (annexin V + and PI + ) cells. Annexin V fluorescein isothiocyanate (FITC) conjugate was added and the sample was analyzed using a Coulter ® epics ® XL-MCL system (Beckman Coulter, Indianapolis, IN, USA).
Gene Expression Microarray
Total RNA that contained both mRNA and ncRNA was isolated from patient samples using the RNeasy kit (Qiagen Inc., Germantown, MD, USA). The quality of the total RNA was confirmed using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA, USA) and the RNA6000 Nano assay (Agilent). For each sample, the 3 in vitro translation (IVT) express kit (Affymetrix, Santa Clara, CA, USA) synthesized biotin-labeled RNA target from 100 ng of the total RNA sample. The 3 IVT kit contains hybrid primers that bind polyA (polydT) as well as random hexamer primers that bind ncRNA sequence. The kit generates cDNA to both polyA (coding) and non-polyA (non-coding) RNAs. A hybridization cocktail that included 10 µg of target was created for each sample. Samples were hybridized to the Genechip Primeview Human Gene Expression probe array cartridge (Affymetrix). The PrimeView Human Gene Expression Array provides comprehensive coverage of the human genome in a cartridge array format. The array is comprised of >530,000 probes covering >36,000 transcripts and variants, which represent >20,000 genes. Arrays contain probes for >20,000 total mature miRNAs, snoRNAs, ncRNAs, and pre-miRNAs. Those probes that demonstrated a cutoff greater or less than 2-fold from normal PCs were further analyzed.
Biostatistical Analysis
ncRNA profiles from drug-naïve and drug-resistant myeloma cells were performed and the statistical significance of the differences was determined using the Student t test with a minimal level of significance of p < 0.05.
Results

Generation of Myeloma Cells Resistant to Proteasome Inhibitors
RPMI8226 myeloma cells were treated with either vehicle (0.05% DMSO) or the proteasome inhibitors (PIs) bortezomib, carfilzomib, or ixazomib (Figure 1 ). Over a period of six months, RPMI8226 cells were exposed to the PIs at successively increased concentrations that ranged from 1 nM up to 100 nM. Each of the three drug-resistant cell lines exhibited a reduced growth rate, as shown by trypan blue staining relative to the drug-naïve parental RPMI8226 cells ( Figure 2 ).
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Drug-Resistant Cells Are Less Sensitive to Proteasome Inhibitor Effects on Cell Viability and Apoptosis
Parental and PI-resistant cells were treated with bortezomib, carfilzomib, or ixazomib and the effect on cell growth and proliferation was determined using the XTT assay ( Figure 3A) . Importantly, each drug-resistant cell line was also resistant to the other two PIs, while the parental cells were sensitive to all PIs. The viability of drug-resistant cells was not affected by the PIs (10 nM), while the growth of parental cells was reduced by ≈80%. The PIs also induced apoptosis in parental cells, as determined by flow cytometry to detect annexin-positive cells ( Figure 3B ). We determined that ≈22-28% of parental cells were annexin-positive after treatment with the three PIs but only 4-6% of the Figure 2 . Growth rate of drug-resistant myeloma cells. The growth rate of parental and drug-resistant cells was determined by counting live cells by trypan blue staining. Shown is the average of triplicate measurements.
Parental and PI-resistant cells were treated with bortezomib, carfilzomib, or ixazomib and the effect on cell growth and proliferation was determined using the XTT assay ( Figure 3A) . Importantly, each drug-resistant cell line was also resistant to the other two PIs, while the parental cells were sensitive to all PIs. The viability of drug-resistant cells was not affected by the PIs (10 nM), while the growth of parental cells was reduced by ≈80%. The PIs also induced apoptosis in parental cells, as determined by flow cytometry to detect annexin-positive cells ( Figure 3B ). We determined that ≈22%-28% of parental cells were annexin-positive after treatment with the three PIs but only 4%-6% of the drug-resistant cells were annexin-positive ( Figure 3B ).
Figure 2.
Growth rate of drug-resistant myeloma cells. The growth rate of parental and drug-resistant cells was determined by counting live cells by trypan blue staining. Shown is the average of triplicate measurements.
Drug-Resistant Cells Are Less Sensitive to Proteasome Inhibitor Effects on Cell Viability and Apoptosis
Parental and PI-resistant cells were treated with bortezomib, carfilzomib, or ixazomib and the effect on cell growth and proliferation was determined using the XTT assay ( Figure 3A) . Importantly, each drug-resistant cell line was also resistant to the other two PIs, while the parental cells were sensitive to all PIs. The viability of drug-resistant cells was not affected by the PIs (10 nM), while the growth of parental cells was reduced by ≈80%. The PIs also induced apoptosis in parental cells, as determined by flow cytometry to detect annexin-positive cells ( Figure 3B ). We determined that ≈22-28% of parental cells were annexin-positive after treatment with the three PIs but only 4-6% of the drug-resistant cells were annexin-positive ( Figure 3B ). (CFZ)-, or ixazomib (IXZ)-resistant cells were exposed to bortezomib, carfilzomib, or ixazomib (10 nM). The XTT assay was used to measure the effect of drugs on MM growth and proliferation. (B) Effect of PIs on the induction of apoptosis in the parental (drug-sensitive) and drug-resistant RPMI8226 cells. Cells were exposed to each PI (10 nM) for 18 h and the percentage of annexin-positive cells was determined by flow cytometry. Shown is the average of triplicate measurements.
Genome-Wide ncRNA Profiling of Parental and Drug-Resistant Myeloma Cells
To detect ncRNAs and lncRNAs that correlated with PI resistance, total RNA was isolated from parental and the three PI-resistant cell lines. ncRNA from these cells was then analyzed using a global, unsupervised approach with Affymetrix-based microarrays. While over 15,000 pre-miRNAs and mature ncRNAs were screened, only 18 human ncRNAs (8 miRNAs and 10 lncRNAs) were expressed with statistically significant differences between the drug-naïve parental cells and the drug-resistant cell lines. Table 1 lists individual miRNAs that were significantly deregulated in PI-resistant cell lines relative to the parental PI-sensitive RPMI8226 cell line. Interestingly, miRNAs 29a, 29b, 29c and the Let-7 family have been previously linked to tumorigenesis [57] [58] [59] . As shown in the heat map ( Figure 4 ) and Table 2 , lnc-Col4A2-1, lnc-PRKCQ-1, lnc-DNAJB11-6, and lnc-MYOT-1 were significantly upregulated in all three PI-resistant cell lines. lncRNAs commonly downregulated in all three PI-resistant cells were also detected. These were lnc-PARD6G-2, lnc-FAM135A, lnc-MTRNR2L1-2, lnc-CD99-6, lnc-CHM-1, lnc-ZNF337-7, and lnc-CXorf64-1 ( Figure 4 ). 
Genome-Wide lncRNA Profiling of Healthy and MM Plasma Cells
Preliminary studies were performed to identify individual lncRNAs that were deregulated in MM. Total RNA was isolated from CD138 + cells obtained from three healthy individuals and three newly diagnosed MM patients. lncRNA expression levels were determined using an unsupervised approach with Affymetrix-based microarrays that contained ≈11,000 lncRNA probes. The analysis identified eight different lnc-RNAs (lnc-Col4A2-1, lnc-ZNF726-4, lnc-DNAJB11-6, lnc-MYOT-1, lnc-PRKCQ-1, lnc-CXADR-1, lnc-ZNF99-6, and lnc-ZNF337-7) that were significantly upregulated in MM CD138 + cells compared to healthy CD138 + cells ( Figure 5 ). Another 10 lnc-RNAs (lnc-ASB7-7, 
Preliminary studies were performed to identify individual lncRNAs that were deregulated in MM. Total RNA was isolated from CD138 + cells obtained from three healthy individuals and three newly diagnosed MM patients. lncRNA expression levels were determined using an unsupervised approach with Affymetrix-based microarrays that contained ≈11,000 lncRNA probes. The analysis identified eight different lnc-RNAs (lnc-Col4A2-1, lnc-ZNF726-4, lnc-DNAJB11-6, lnc-MYOT-1, lnc-PRKCQ-1, lnc-CXADR-1, lnc-ZNF99-6, and lnc-ZNF337-7) that were significantly upregulated in MM CD138 + cells compared to healthy CD138 + cells ( Figure 5 ). Another 10 lnc-RNAs (lnc-ASB7-7, lnc-DEFB115-7, lnc-FAM135A, lnc-MTRN2L1-2, lnc-ZNF727-19, lnc-DEFB115-3, lnc-ZNF337-22, lnc-ZNF337-2, lnc-ZNF727-18, and lnc-PARD6G-2) were significantly downregulated in MM CD138 + cells compared to healthy CD138 + cells ( Figure 5 ). Then, we analyzed lncRNAs deregulated in PI-resistant cells relative to PI-sensitive cells. The results indicated that lnc-Col4A2-1, lnc-ZNF726-4, lnc-DNAJB11-6, lnc-MYOT-1, lnc-PRKCQ-1, lnc-CXADR-1, and lnc-ZNF99-6 were upregulated in PI-resistant cells relative to parental cells. These same lncRNAs were also upregulated in MM CD138 + cells relative to healthy CD138 + cells. Figure 5 lists those lncRNAs deregulated in both PI-resistant cells and MM CD138 + cells.
Genes 2016, 7, 84 8 of 13 DNAJB11-6, lnc-MYOT-1, lnc-PRKCQ-1, lnc-CXADR-1, and lnc-ZNF99-6 were upregulated in PIresistant cells relative to parental cells. These same lncRNAs were also upregulated in MM CD138 + cells relative to healthy CD138 + cells. Figure 5 lists those lncRNAs deregulated in both PI-resistant cells and MM CD138 + cells. 
Discussion
The identification of lncRNAs deregulated in myeloma cells resistant to PIs provides exciting new information to help unravel drug resistance mechanisms and identifies potential new therapeutic targets to improve cancer treatment. In healthy cells under physiologic conditions, multiple lncRNAs converge to maintain a proper balance of proliferation, differentiation, and death ( Table 3 ). In pathologies such as human cancers, lncRNAs are deregulated and have profound consequences on viability and therapeutic response. Importantly, a single lncRNA can regulate multiple targets, e.g., miRNAs, mRNAs, and genes. In cancer, the loss of a tumor-suppressive lncRNA may enhance the expression of target oncogenes, whereas increased expression of an oncogenic lncRNA may repress tumor suppressors. This realization has resulted in studies to understand the pathways regulated by lncRNAs using cell-based pre-clinical model systems and to comprehend the feasibility of restoring tumor-suppressive lncRNAs for cancer therapy.
A recent report investigated lncRNAs as biomarkers for predicting survival in MM patients (55) . In addition, metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) has been found to be overexpressed in MM and may represent a marker to predict MM progression (53) . Finally, a recent study identified deregulated lncRNAs putatively associated with MM pathogenesis and possibly linked to the accepted multi-step process underlining the different stages of the disease (59) . The present study was focused on the uniformly fatal plasma cell dyscrasia MM as a model to study the role of lncRNAs in cancer and drug resistance. Through such an approach, microarray-based profiling revealed a panel of lncRNAs differentially regulated in myeloma cells. The molecular basis of resistance to proteasome inhibitors is a fundamental biologic problem that impedes translational 
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To the best of our knowledge, this is the first report describing the global expression profiles of lncRNAs in samples of MM from patients and PI-resistant MM cells. Notably, our study identified 8 lncRNAs that were specifically upregulated in both MM CD138 + cells compared to healthy CD138 + cells and PI-resistant cells relative to parental cells. Another nine lncRNAs were significantly downregulated in both MM CD138 + cells compared to healthy CD138 + cells and PI-resistant cells relative to parental cells ( Figure 5 ). Despite the fact that the mechanism and the function of lncRNAs, as well as the consequences of their deregulation, remain to be fully clarified, many of the individual lncRNAs identified here that are deregulated in MM CD138 + cells are also deregulated in PI-resistant MM cells. Therefore, PI-resistant MM cell lines represent a reasonable model system to investigate the role of individual lncRNAs in the disease process and drug-resistance. Many of the prior studies that investigated ncRNAs in MM, have not looked at individual patients but rather present the collective average of up-and downregulated ncRNAs in all patients.
ncRNA replacement therapy is an innovative strategy that could save patients from ineffective treatment, improve QOL, enhance OS, and reduce the devastating impact of cancer therapy on the healthcare system [55] [56] [57] [58] (Figure 6 ). Certain ncRNAs function as bona fide tumor suppressors and synthetic versions of these ncRNAs robustly interfere with tumor growth in animal models to strongly support the investigation and clinically development of ncRNA replacements. There are two main therapeutic strategies related to targeting ncRNAs. ncRNAs that acquire a gain-of-function in the diseased tissue, e.g., oncogenic ncRNAs, can be inhibited by using ncRNA antagonists, such as antagomirs. Alternatively, ncRNAs that show a loss of function, e.g., tumor suppressors, can be restored by using ncRNA mimics or replacements. ncRNA replacement therapy involves the re-introduction of ncRNAs into diseased tissues to reactivate pathways that drive a therapeutic response. Reactivation of these ncRNA-regulated pathways can interfere with the oncogenic properties of cancer cells, blocking uncontrolled proliferation and inducing apoptosis. Based upon our pre-clinical studies, we propose to investigate these ncRNAs as attractive targets for therapeutic intervention. Ultimately, our goal is to understand the roles of ncRNAs in cancer and the potential for manipulating miRNAs for cancer therapy as these molecules make their way towards the clinic.
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Conclusions
We have identified a curated panel of deregulated lncRNAs in common within myeloma cells generated with acquired resistant to three different clinically-relevant PIs and MM patients. Our study has shown the value of PI-resistant cell lines as a preliminary model system to address the mechanistic role of individual lncRNAs in MM and the development of drug resistance. The results prioritize specific lncRNAs to be studied in terms of defining their role in myelomagenesis and the development of drug resistance. Further investigation is warranted to shed light on the precise mechanism of action of these lncRNAs and identify their biological functions and targets.
